When Biogen received approval for a breakthrough drug for treating multiple sclerosis, it had to quickly get the product to market. So it circumvented the traditional supply chain and joined with partners to become a virtual manufacturer.When the biotech pioneer had to get a blockbuster drug to market fast, it didn't lock itself into a rigid supply chain. It joined with partners to become a virtual manufacturer.